biostudies-literatureWieczorek LFogarty Epidemiology Research Training for Public Health Impact in Nigeria programU.S. President's Emergency Plan for AIDS ReliefNIAID NIH HHSFIC NIH HHSNIMH NIH HHSU.S. Department of DefenseNational Institutes of HealthNIH HHSU.S. President’s Emergency Plan for AIDS Relief148https://www.ebi.ac.uk/biostudies/studies/S-EPMC11218331biostudies-literatureUnknown21(1)The magnitude of the HIV-1 epidemic in Nigeria is second only to the subtype C epidemic in South Africa, yet the subtypes prevalent in Nigeria require further characterization. A panel of 50 subtype G and 18 CRF02_AG Nigerian HIV-1 pseudoviruses (PSV) was developed and envelope coreceptor usage, neutralization sensitivity and cross-clade reactivity were characterized. These PSV were neutralized by some antibodies targeting major neutralizing determinants, but potentially important differences were observed in specific sensitivities (eg. to sCD4, MPER and V2/V3 monoclonal antibodies), as well as in properties such as variable loop lengths, number of potential N-linked glycans and charge, demonstrating distinct antigenic characteristics of CRF02_AG and subtype G. There was preferential neutrVirology journalDifferences in neutralizing antibody sensitivities and envelope characteristics indicate distinct antigenic properties of Nigerian HIV-1 subtype G and CRF02_AG.PMC11218331NU2GGH002099R01 MH099001, R01 AI120913, R01 MH110358R01 MH110358D43 TW010051R01 AI120913D43TW010051W81XWH-11-2-0174, W81XWH-07-2-0067, W81XWH-18-2-0040R01 MH099001Poltavee KLangat EOdo FAPolonis VRSchech SOchieng CRamadhani HNabanoba CFrancisco LEluwa RWangiri PKiliba PKiptoo ITiamiyu ABAbimiku AOkeke NNnadi NMbachu MLangat RAdebajo SAsuquo MWieczorek LMfumbulwa HMukanza BChangwony EBaghendaghe EGolway ABirungi HDavid GSuleiman ANjegite JNwandu HHu FBohince KBarrows BElemere JOwuoth JAbdu RRotich JMankiewicz SNajjuma ELeelgo MRotich LEngoke GOlomi WSchoen JObambo KBaral SKafeero CVasan STiamiyu AChumba ECharurat MKapkiai JLee EOnonaku UMeyo JTonui EChioma EKokogho AChang DParikh ABii MShoyemi EGitonga DTowett JOkoye IMebrahtu TSuja GAkiga RZemil MRehema WMaganga LSing'oei VUmejo LKiprotich SAgbaim CAOpiyo FOmondi BWaiswa MNwalozie JNatalie UALauretta OIIdi VSemwogerere MMichael NLChelangat EMbwayu FRobb MBartolanzo DEller LAMilazzo MAdegbite TMusingye EMaswai JMaggaga OObonyo MParker ZLinus AUSanders-Buell EAbayomi ANaluyima PAiro AMalia JTovanabutra SWangare SKibuuka HReynolds AMkondoo DModi EHern JLabosso KOchai IImbach MWandege JOkolo CKesi ZBOntango SOtieno SLwebuge WOkwaro CAdelakun ASomi NMwamwaja JAFRICOS and TRUST/RV368 Study GroupsTegamanyi JAdai WDuff ENgtech BMartinez ECheruiyot LCharurat MEAdimo OMohammed SSRosemary NKisinda AMutebe HChigbu-Ukaegbu IHarrison NTumusiime RMwaisanga GEmmanuel AMwaipopo MIroezindu MOdeyemi SEnas OSong KTindikahwa AOkanigbuan BLueer CGaydos CKorir LOgari CNowak RBlattner WKhamadi SGervas REdwin PKenoly IKAke JALombardi KAzuakola NSsentogo FNgeno AKimetto JAoko IZziwa GNanteza CCrowell TAChenine ALKasembeli AOnyango MOmar BPeel SMsigwa JRodriguez-Hart CFaith IAkinwale EFrancis FIOwanza OTNgeno JLando CNamulondo PAdamu YMolnar SMetet IBahemana EfalseDifferences in neutralizing antibody sensitivities and envelope characteristics indicate distinct antigenic properties of Nigerian HIV-1 subtype G and CRF02_AG.The magnitude of the HIV-1 epidemic in Nigeria is second only to the subtype C epidemic in South Africa, yet the subtypes prevalent in Nigeria require further characterization. A panel of 50 subtype G and 18 CRF02_AG Nigerian HIV-1 pseudoviruses (PSV) was developed and envelope coreceptor usage, neutralization sensitivity and cross-clade reactivity were characterized. These PSV were neutralized by some antibodies targeting major neutralizing determinants, but potentially important differences were observed in specific sensitivities (eg. to sCD4, MPER and V2/V3 monoclonal antibodies), as well as in properties such as variable loop lengths, number of potential N-linked glycans and charge, demonstrating distinct antigenic characteristics of CRF02_AG and subtype G. There was preferential neutr2024-01-01T00:00:00Z2024 Jun2025-04-04T23:54:40.41Z2025-04-04T23:54:40.41ZS-EPMC112183313895181410.1186/s12985-024-02394-y